Showing results (231-240 of 308) with videos related to
Sort By:
Pageof 31
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.The Journal of Allergy and Clinical Immunology|March 6, 2012
Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signalingSaeko Nakajima, Botond Z Igyártó, Tetsuya Honda, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 30, 2021
TSLP-Driven Chromatin Remodeling and Trained Systemic Immunity after Neonatal Respiratory Viral InfectionCarrie-Anne Malinczak, Abhijit Parolia, Wendy Fonseca, et al.The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.The Journal of Allergy and Clinical Immunology|September 5, 2020
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trialPascal Demoly, Jonathan Corren, Peter Creticos, et al.Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 26, 2023
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitizationJonathan Corren, Nicola A Hanania, William W Busse, et al.Blood|August 29, 2009
CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia miceCarol H Miao, Benjamin R Harmeling, Steven F Ziegler, et al.ERJ Open Research|February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthmaJonathan Corren, Fred Reid, Rachel Moate, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.Pageof 31